Pen testing · Digital health & life sciences
Penetration Testing for Biotech & Pharma Companies
Penetration testing for a biotech or pharma company has to answer a question most engagements never face: how do you probe a validated GxP system for exploitable weaknesses without invalidating the record that lets it run production data? The trigger is usually a partnering counterparty's diligence checklist, a new portal built for CROs or investigators, or the first real look at what an ELN or LIMS exposes to the internet. We scope testing around what can be probed directly, what needs a controlled non-production copy, and what a partner's security team will actually want to see.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What penetration testing has to cover in a biotech or pharma environment
The attack surface here splits between systems that can be tested freely and systems where testing itself carries operational risk.
External portals for CROs, sites and investigators
Web applications granting outside parties access to trial or partner data, often built quickly for a single study and left running long after.
ELN and LIMS applications
Electronic lab notebooks and lab information management systems holding unpublished research and sample data, frequently exposed through web interfaces with uneven authentication.
Corporate infrastructure separate from validated systems
Email, file storage, CRM and ERP platforms that sit outside GxP validation and can be tested with standard methodology, but often hold IP and PSP-adjacent data nonetheless.
Any sponsor-operated integration into a hub vendor
APIs or file-transfer connections between the sponsor's systems and a PSP hub or specialty pharmacy, a boundary that rarely gets tested by either party alone.
Regulatory map
Why penetration testing matters here beyond a generic security requirement
The case for testing in this sector runs through partnering contracts and inspection expectations as much as through any single statute.
Data-integrity expectations under GxP inspection
Health Canada's inspection programs expect computerised systems supporting trials and manufacturing to be secure as well as validated, and untested external-facing access points are a common gap inspectors raise.
Licensing and partnering diligence expectations
A partnering MSA or licensing term sheet increasingly asks for evidence of independent security testing before data-sharing begins, and 'we haven't tested it' is not an answer that survives a serious diligence process.
PIPEDA's safeguards principle
Canadian privacy law requires safeguards proportional to the sensitivity of the information held, and penetration testing is the standard way to demonstrate that portals and applications actually meet that bar.
What goes wrong
What penetration testing here is designed to find before an attacker does
The scenarios that matter most in this sector combine a technical weakness with a data category the company cannot afford to lose.
Weak authentication on external-facing portals
CRO and investigator portals built for a single study often carry the weakest access controls in the company, precisely because they were never expected to still be running years later.
Ransomware entering through an untested trial-adjacent system
A shared eClinical vendor's 2020 ransomware incident forced sites onto pen and paper mid-study, a scenario that starts with exactly the kind of unpatched or untested access point testing is meant to surface.
ELN or LIMS misconfiguration exposing unfiled research
A permissions error in a lab information system can quietly expose sequences or process data to anyone with a login, long before anyone notices the access pattern.
Credential-based access into consumer-facing health platforms
Accounts without multi-factor authentication remain the entry point regulators keep pointing to after large-scale credential-stuffing incidents against genetic and health-profile platforms.
Our pen testing for biotech & pharma companies
What our penetration testing covers for a biotech or pharma company
The same four elements our penetration testing service always delivers, applied with the validation constraints this sector requires.
Vulnerability exploration scoped around validation status
High-level testing across applications and portals, with validated GxP systems tested against a controlled non-production copy rather than the live production environment wherever validation rules require it.
Response capability observation
Insight into how your team notices and reacts during simulated attempts, useful groundwork for the incident response plan a licensing partner will also want to see.
Defensive improvement guidance sequenced for your deal calendar
Directional feedback prioritized so the findings most likely to matter to a partner's diligence review get addressed before that review happens, not after.
Standards and expectation awareness for GxP and partner audiences
Context connecting testing results to what GxP inspectors and partnering security teams typically look for, so findings translate directly into language both audiences understand.
How the engagement runs
How penetration testing runs without disturbing validated systems
Scoping happens before any testing starts, specifically to separate what can be tested live from what needs a safer path.
Step 1
Classify the environment
We separate validated GxP systems from general corporate and portal infrastructure, and agree in writing what can be tested directly and what requires a non-production copy.
Step 2
Test
External portals, ELN/LIMS applications and corporate infrastructure are probed using standard methodology, with validated systems handled through the agreed safer path.
Step 3
Report
Findings are documented in a form your security lead, your QA function and a partner's diligence team can each use for their own purpose.
Step 4
Guide remediation
We provide directional guidance on fixing what was found, sequenced against any upcoming diligence review or inspection.
What it costs
What determines penetration testing cost for a biotech or pharma company
Cost depends on how many external portals and applications are in scope, how much of the environment sits behind GxP validation and therefore needs a non-production testing path, and how large the corporate infrastructure footprint is beyond the lab.
A company with one CRO-facing portal and a small corporate footprint costs less to test than one running multiple investigator portals, an ELN, a LIMS and a hub-vendor integration at once. We scope pricing after reviewing what is validated, what is external-facing, and what a partner's questionnaire is likely to ask about.
Biotech & Pharma Companies: Pen testing questions, answered
Yes, but not always against the live production instance. Where a system's validated state cannot tolerate the kind of probing a real test requires, we test against a controlled non-production copy configured to mirror production, so findings are still meaningful without triggering a revalidation event.
Partners typically expect evidence of independent testing covering authentication, access controls and common web-application weaknesses on anything reachable from outside the company, plus a documented remediation history. A test report alone rarely satisfies a serious diligence team without proof that findings were actually closed.
Testing is scoped specifically to avoid that outcome. Systems supporting an active trial or a live manufacturing run are either tested against a non-production environment or scheduled during a window agreed with your operations team, rather than tested without coordination.
Annually at minimum, and again whenever a new external-facing portal launches, a major system changes, or a partnering deal is approaching diligence. A test that is a year and a half old rarely satisfies a partner's questionnaire even if nothing has technically changed.
No. Testing covers systems the company itself operates — portals, ELN, LIMS, corporate infrastructure — while a CRO's or hub vendor's own systems are reviewed through vendor security oversight rather than direct testing, since the company does not control that infrastructure.
More for biotech & pharma companies
Other services for this niche
- Privacy & security for biotech & pharma companies — overview
- Virtual CISO
- Virtual Privacy Officer
- Incident Response Planning
- Privacy & Security Policy Development
- Privacy & Security Training
- Vendor Security Review & Questionnaire Support
- ISO 27001 Readiness
- HIPAA Readiness
- M&A Privacy & Security Due Diligence
About this service
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.